Broad Institute Chemical Biology Pipeline
The Chemical Biology and Novel Therapeutics Platforms have been established at the Broad Institute to accomplish two goals: (1) discover small molecules that impact biology and medicine; and (2) innovate the process through which probes and drugs are discovered and developed. To accomplish these goals effectively, we plan to undertake the most innovative chemical biology screening projects arising from the broader scientific community.
This page provides the resources necessary to learn about and apply to engage with the Broad Institute Chemical Biology Platform to undertake your high-throughput screening project.
Application Package
The application package (last updated 09/09/11) includes the following documents:
- Broad Institute Chemical Biology Platform and Novel Therapeutics Platform: Overview of Principles and Processes: General principles for working effectively with the Chemical Biology Platform, and an overview of the pipelines for investigators to propose and execute projects
- Broad Institute Chemical Biology Platform HTS Application Process and Guidelines: Overview of HTS application process
- Broad Institute Chemical Biology Platform High-Throughput Screening Application: To be completed for each new HTS project proposal
- Broad Institute High-Throughput Assay Readiness Assessment: To be completed for projects favorably evaluated by the Application Review Committee
- Broad Institute Chemical Biology Platform Screening Services Memorandum of Understanding (MOU): To be completed for projects that are assessed as HTS-ready and accepted for execution
- Broad Institute Chemical Biology Platform Incoming Materials Transfer Agreement (MTA): To be completed for projects that are assessed as HTS-ready and accepted for execution
Application Process
After carefully reviewing the Broad Institute Chemical Biology Platform and Novel Therapeutics Platform: Overview of Principles and Processes document, we request that all investigators complete a screening application, describing the scientific rationale and screening approach for the project. Please initiate the review of the Memorandum of Understanding (MOU) and Materials Transfer Agreement (MTA) with your institution’s Technology Transfer Office and/or Sponsored Research Office prior to submitting an application.
Applications will be reviewed by an Application Review Committee consisting of experts in basic biology, disease biology and drug discovery. If your application is aligned with the Broad Institute mission, as determined by the Application Review Committee, we will meet with you (in person or by phone) to review the readiness status of your assay. This discussion will be guided by the Broad Institute High-Throughput Assay Readiness Assessment document. Assays that are deemed ready for assay development at the facility and which meet secondary considerations (balancing of the Broad HTS portfolio, funding obligations, technical feasibility etc.) will be accepted for execution during the next available screening slot at the facility. Accepted projects will require a completed MOU and MTA to be in place prior to project initiation.
Application Deadlines
The upcoming HTS application deadlines are:
- June 7, 2013
- September 6, 2013
- December 6, 2013
We estimate that the review process will take ~6 weeks from the application receipt deadline to selection of assays for execution.
Contact Us
If you have any questions, please email htsfacility@broadinstitute.org and your request will be directed to the relevant contact.
Related Information
- Broad Institute Chemical Biology platform
- Broad Insitute 'PsychHTS' Initiative: for more information regarding applications with a neuropsychiatric disease focus
- MLPCN, Broad Institute Probe Development Center (BIPDeC) pipeline: for information on the R03 endorsement process
